NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
6/8 — Strong
FETZIMA (levomilnacipran hydrochloride) by AbbVie is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of reuptake at serotonin and norepinephrine transporters. Approved for major depressive disorder (mdd) in adults (). First approved in 2013.
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FETZIMA (levomilnacipran HCl) is an oral extended-release SNRI approved for Major Depressive Disorder in adults. It works by potentiating serotonin and norepinephrine in the central nervous system through selective reuptake inhibition at serotonin and norepinephrine transporters. The mechanism is thought to enhance monoaminergic neurotransmission to alleviate depressive symptoms.
$0.029BPart D
Peak5.5 years to LOEAt peak lifecycle with $29M in Part D spending (2023), FETZIMA maintains a stable but modest commercial footprint in a mature SNRI category.
Mechanism of Action
unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of reuptake at serotonin and norepinephrine transporters. Non-clinical studies have shown that levomilnacipran is a potent and selective serotonin and…
Indications (1)
Career Relevance
FETZIMA offers limited immediate career growth opportunities given zero linked job openings and mature peak-stage positioning in a crowded SNRI market. Roles are primarily commercial and defensive in nature, focused on market share protection and managed care access rather than launch energy or clinical innovation.
Worked on FETZIMA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.